Free Trial

180 Life Sciences (ATNF) Competitors

180 Life Sciences logo
$2.53 +0.13 (+5.42%)
As of 09/23/2025

ATNF vs. ALGS, DRRX, CELU, NRXP, GANX, DTIL, PRLD, ICCC, GNTA, and CUE

Should you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Aligos Therapeutics (ALGS), DURECT (DRRX), Celularity (CELU), NRx Pharmaceuticals (NRXP), Gain Therapeutics (GANX), Precision BioSciences (DTIL), Prelude Therapeutics (PRLD), ImmuCell (ICCC), Genenta Science (GNTA), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.

180 Life Sciences vs. Its Competitors

180 Life Sciences (NASDAQ:ATNF) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Aligos Therapeutics has a consensus target price of $50.00, indicating a potential upside of 365.12%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aligos Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

180 Life Sciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 38.2% of 180 Life Sciences shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

180 Life Sciences has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/A-$6.17M-$15.07-0.17
Aligos Therapeutics$3.94M16.78-$131.21M-$19.79-0.54

180 Life Sciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat 180 Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A -141.25% -80.77%
Aligos Therapeutics -2,337.24%-22.41%-12.09%

In the previous week, Aligos Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company Overall Sentiment
180 Life Sciences Neutral
Aligos Therapeutics Neutral

Summary

Aligos Therapeutics beats 180 Life Sciences on 9 of the 14 factors compared between the two stocks.

Get 180 Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATNF vs. The Competition

Metric180 Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.28M$3.11B$5.74B$10.35B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-0.1720.9076.3526.43
Price / SalesN/A253.84466.9091.03
Price / CashN/A46.3537.4661.85
Price / Book0.879.8313.186.39
Net Income-$6.17M-$52.73M$3.29B$271.22M
7 Day Performance9.52%4.84%2.50%2.78%
1 Month Performance-23.33%6.37%4.59%7.35%
1 Year Performance35.29%19.14%73.81%29.74%

180 Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNF
180 Life Sciences
N/A$2.53
+5.4%
N/A+29.0%$15.28MN/A-0.177Gap Up
ALGS
Aligos Therapeutics
3.378 of 5 stars
$9.53
-1.4%
$50.00
+424.7%
+26.5%$59.48M$3.94M-0.4890Gap Up
DRRX
DURECT
1.6403 of 5 stars
$1.91
flat
N/AN/A$59.31M$1.66M-19.1080
CELU
Celularity
1.292 of 5 stars
$2.12
-4.5%
$6.00
+183.0%
-24.3%$59.26M$54.22M-0.67220
NRXP
NRx Pharmaceuticals
3.2852 of 5 stars
$2.87
-3.4%
$34.50
+1,102.1%
+72.7%$58.83MN/A-1.282News Coverage
Positive News
Gap Up
GANX
Gain Therapeutics
2.7088 of 5 stars
$1.74
+10.1%
$8.00
+359.8%
+12.9%$56.80M$50K-2.7620News Coverage
DTIL
Precision BioSciences
3.9627 of 5 stars
$4.86
+1.7%
$47.00
+867.1%
-48.0%$56.34M$68.70M-0.55200
PRLD
Prelude Therapeutics
3.0772 of 5 stars
$1.01
+2.6%
$4.00
+296.0%
-56.5%$55.74M$7M-0.62120News Coverage
Analyst Forecast
ICCC
ImmuCell
1.0099 of 5 stars
$6.25
+4.9%
N/A+71.4%$53.91M$26.49M32.9070News Coverage
Positive News
Gap Down
GNTA
Genenta Science
2.5807 of 5 stars
$2.97
+3.7%
$25.00
+742.9%
-20.5%$52.31MN/A0.007Positive News
CUE
Cue Biopharma
1.36 of 5 stars
$0.70
+4.7%
N/A+48.1%$51.65M$9.29M-1.2660

Related Companies and Tools


This page (NASDAQ:ATNF) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners